

Special Issue

mRNA Vaccines: Pioneering the Future of Vaccination

Message from the Guest Editors

Amid the devastation of the COVID-19 pandemic, mRNA vaccines have risen to the occasion. While early IVT-mRNA was limited by instability, high immunogenicity, and poor translatability, current advances in mRNA synthesis have significantly enhanced antigen expression and protective immunity.

The impact of mRNA vaccines on cancer and infectious disease remains in its preliminary stages. Trials in animal-based models and human individuals exhibit substantial differences in expression and immune response. The mechanisms of these vaccines in animal models and humans also require further investigation. To achieve a more extensive understanding of the recent scientific knowledge and current trends in mRNA vaccine development, this Special issue is focused on the recent scientific and technical advances including, but not limited to, mRNA vaccines. Based on your extensive knowledge and experience, we invite you to contribute an original report, original observation or review.

Guest Editors

Dr. Zhongfeng Ye

Dr. Yu Zhao

Dr. Minghui Yang

Deadline for manuscript submissions

closed (31 January 2025)



Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed



mdpi.com/si/165511

Vaccines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
vaccines@mdpi.com

[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)





Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed



[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)



About the Journal

Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

Editor-in-Chief

Prof. Dr. Ralph A. Tripp

Department of Infectious Diseases, College of Veterinary Medicine,
University of Georgia, Athens, GA 30602-7387, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Medicine, Research and Experimental) /
CiteScore - Q1 (Pharmacology (medical))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 18.1 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the second half of 2025).